Nasdaq – Page 2 – PharmaLive

Three Biopharma Companies Make Nasdaq Debut

Biopharma Companies, Business, Cancer Therapies, Financing, Initial Public Offering (IPO), Nasdaq, Series B, Series C Financing, Stocks

Three biopharma companies became publicly traded companies and made their debut on the Nasdaq this week.

March 26, 2021/by Andrew Humphreys

Pfizer Spinout Cerevel Therapeutics Begins Trading on the Nasdaq

Business, Clinical Trials, Mergers, Nasdaq, Neuroscience, Parkinson’s disease, R&D, Spin-Outs, Trading

Cerevel Therapeutics began trading on the Nasdaq.

October 29, 2020/by Andrew Humphreys

Metuchen and Neurotrope Merge to Form Men’s Health-Focused Petros Pharmaceuticals

Appointments, Business, Deals, Erectile dysfunction, Men's Health, Mergers, Nasdaq, People on the Move, Product Pipelines, Shares, Stocks

Neurotrope and Metuchen Pharmaceuticals announced the companies have merged in an all-stock deal to form Petros Pharmaceuticals, which is focused on men’s health conditions.

May 18, 2020/by BioSpace

Amgen to Cut More U.S. Jobs

American Depositary Shares (ADS), Business, California, Cardiovascular Disease, China, Generics, Inflammatory Diseases, Job Cuts, Layoffs, Massachusetts, Nasdaq, Neuroscience, Oncology

Amgen filed a Worker Adjustment and Retraining in California with plans to cut 172 jobs at the company’s headquarters and U.S. field operations effective December 31, 2019.

November 20, 2019/by BioSpace

Harpoon Therapeutics Joins 2018 IPO Game

Biotech, Business, Cancer, Clinical Studies, Hematologic malignancies, Immuno-oncology, Immunotherapies, Initial Public Offering (IPO), Lesions, Nasdaq, Ovarian Cancer, Prostate Cancer, Solid Tumors, T-Cells, U.S. Securities and Exchange Commission (SEC)

South San Francisco-based Harpoon Therapeutics is tapping into the white-hot IPO magic that was one of the hallmarks of 2018 for the biotech industry.

December 28, 2018/by BioSpace